A synthetic peptide for use as a blocking control in assays to test for specificity of VISA antibody, Alternative Names: VISA control peptide, VISA antibody Blocking Peptide, Anti-VISA Blocking Peptide, Virus-Induced Signaling Adapter Blocking Peptide, CARDIF Blocking Peptide, DKFZp666M015 Blocking Peptide, FLJ27482 Blocking Peptide, FLJ41962 Blocking Peptide, IPS-1 Blocking Peptide, KIAA1271 Blocking Peptide, MAVS Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
MAVS
(Mitochondrial Antiviral Signaling Protein (MAVS))
Synonyme
CARDIF Peptide, IPS-1 Peptide, IPS1 Peptide, VISA Peptide, D430028G21Rik Peptide, Visa Peptide, cardif Peptide, wu:fj20d04 Peptide, zgc:158392 Peptide, mitochondrial antiviral signaling protein Peptide, MAVS Peptide, Mavs Peptide, mavs Peptide
Hintergrund
Double-stranded RNA viruses are recognised in a cell type-dependent manner by the transmembrane receptor TLR3 or by the cytoplasmic RNA helicases MDA5 and RIGI (ROBO3). These interactions initiate signaling pathways that differ in their initial steps but converge in the activation of the protein kinases IKKA (CHUK) and IKKB (IKBKB), which activate NFKB, or TBK1 and IKKE (IKBKE), which activate IRF3. Activated IRF3 and NFKB induce transcription of IFNB (IFNB1). For the TLR3 pathway, the intermediary molecule before the pathways converge is the cytoplasmic protein TRIF (TICAM1). For RIGI, the intermediary protein is mitochondria-bound VISA.